|
3 Companies |
|
5 Products |
|
5 Products |
|
6 Mechanisms of Action |
|
0 Trials |
|
12 News |
|
- | Campath (alemtuzumab) / Sanofi
Enrollment change: Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders (clinicaltrials.gov) - Dec 5, 2017
P=N/A, N=3, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=37 --> 3
- miglustat / Generic mfg.
Trial completion: Pharmacokinetics and Tolerability of Zavesca (clinicaltrials.gov) - May 19, 2016
P2, N=5, Completed, Sponsor: The Hospital for Sick Children
N=37 --> 3 Active, not recruiting --> Completed
- Trial completion, Gene therapy: Gene Therapy for Tay-Sachs Disease (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=4, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Recruiting --> Completed
- Trial termination: UCBT-002: ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases (clinicaltrials.gov) - Jul 8, 2014
P3, N=40, Terminated, Sponsor: Aldagen
Recruiting --> Completed Suspended --> Terminated; Terminated - Sponsor Decision
- Campath (alemtuzumab) / Sanofi
Trial primary completion date: Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders (clinicaltrials.gov) - May 14, 2014
P=N/A, N=37, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Suspended --> Terminated; Terminated - Sponsor Decision Trial primary completion date: Jun 2020 --> Nov 2013
- Campath (alemtuzumab) / Sanofi
Trial completion date: Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders (clinicaltrials.gov) - May 14, 2014
P=N/A, N=37, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Jun 2020 --> Nov 2013 Trial completion date: Jun 2020 --> Nov 2013
- Campath (alemtuzumab) / Sanofi
Trial completion: Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders (clinicaltrials.gov) - May 14, 2014
P=N/A, N=37, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial completion date: Jun 2020 --> Nov 2013 Recruiting --> Completed
- Gene therapy: Gene Therapy for Tay-Sachs Disease (clinicaltrials.gov) - Jun 3, 2013
P=N/A, N=5, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
- pyrimethamine / Generic mfg.
Trial withdrawal: A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis (clinicaltrials.gov) - Feb 20, 2013
P1, N=0, Withdrawn, Sponsor: Exsar Corporation
Recruiting --> Completed Suspended --> Withdrawn
- pyrimethamine / Generic mfg.
Enrollment change: A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis (clinicaltrials.gov) - Feb 20, 2013
P1, N=0, Withdrawn, Sponsor: Exsar Corporation
Suspended --> Withdrawn N=20 --> 0
- Campath (alemtuzumab) / Sanofi
Enrollment open: Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders (clinicaltrials.gov) - Jul 17, 2012
P=N/A, N=37, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=20 --> 0 Not yet recruiting --> Recruiting
- pyrimethamine / Generic mfg.
Trial completion: Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) (clinicaltrials.gov) - Feb 21, 2012
P1/2, N=20, Completed, Sponsor: The Hospital for Sick Children
Not yet recruiting --> Recruiting Recruiting --> Completed